Clinical Trials at Lipson Cancer Institute

Breast Studies

CCTG MA.39 Tailor RT

Principal Investigator: Sheema Chawla, MD

Title: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Locations: Rochester General Hospital and Linden Oaks

Status: Accruing

ClinicalTrials.gov Link: NCT03488693

IORT Registry

Principal Investigator: Khusraw Sabit, MD

Title: Intra-Operative Radiation Therapy (IORT) Using the IntraBeam® System – A Registry Protocol

Locations: Rochester General Hospital and Linden Oaks

Status: Accruing

Gilead ASCENT- 05

Principal Investigator: Farhan Imran, MD

Title: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer who have Residual Invasive Disease after Surgery and Neoadjuvant Therapy

Locations: Rochester General Hospital and Linden Oaks

Status: Accruing

ClinicalTrials.gov Link: NCT05633654

 

Hematological Neoplasms and Disorder Studies

MM Registry

Principal Investigator: Saad Jamshed, MD

Title: Observational Registry Collecting Data on Patients Diagnosed with Multiple Myeloma

Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital

Status: Accruing

MYELOMATCH

Principal Investigator: Maria Sbenghe, MD

Title: MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials

Locations: Rochester General Hospital

Status: Accruing

ClinicalTrials.gov Link: NCT05564390

Janssen HALO MM Registry

Principal Investigator: Saad Jamshed, MD

Title: A Post-Authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)

Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital

Status: Accruing

SID Registry

Principal Investigator: Saad Jamshed, MD

Title: Secondary Immunodeficiency (SID) Registry for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma

Locations: Rochester General Hospital and Linden Oaks

Status: Accruing

Celgene CA057 SUCCESSOR-1

Principal Investigator: Saad Jamshed, MD

Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)

Locations: Rochester General Hospital and Linden Oaks

Status: Accruing

ClinicalTrials.gov Link: NCT05519085

SWOG S1803 DRAMMATIC

Principal Investigator: Saad Jamshed, MD

Title: Phase 3 Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC)

Locations: Rochester General Hospital and Linden Oaks

Status: Accruing

ClinicalTrials.gov Link: NCT04071457

Anthos ASTER (ANT-007)

Principal Investigator: Greg Connolly, MD

Title: A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE

Locations: Rochester General Hospital and Linden Oaks

Status: Accruing

ClinicalTrials.gov Link: NCT05171049

 

Thoracic Studies

Alliance A151216 ALCHEMIST

Principal Investigator:  Mehul Patel, MD

Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Locations: Rochester General Hospital and Linden Oaks

Status: Accruing

Clinical Trials.gov Link: NCT02194738

Alliance A081801

Principal Investigator: Mehul Patel, MD

Title: Integration of Immunotherapy into Adjuvant Therapy for Resected Non-Small Cell Lung Cancer: ALCHEMIST CHEMO-IO (ACCIO)

Locations: Rochester General Hospital and Linden Oaks

Status: Accruing

ECOG-ACRIN E4512

Principal Investigator: Mehul Patel, MD

Title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Locations: Rochester General Hospital and Linden Oaks

Status: Accruing

ClinicalTrials.gov Link: NCT02201992

JAZZ EMERGE

Principal Investigator: Mehul Patel, MD

Title: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca

Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital

Status: Accruing

ClinicalTrials.gov Link: NCT04894591

VERACYTE NIGHTINGALE

Principal Investigator: Jayashri Bhaskar, MD

Title: Clinical Utility of Management of Patients with CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier – with Familiarization

Locations: Rochester General Hospital

Status: Accruing

 

Gastrointestinal Studies

ALLIANCE A032103 MODERN

Principal Investigator: Maria Sbenghe, MD

Title: MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer

Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital 

Status: Accruing

ClinicalTrials.gov Link: NCT05987241

ECOG-ACRIN EA2192 APOLLO

Principal Investigator: Amy Bodrog, MD

Title: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital

Status:Accruing

ClinicalTrials.gov Link: NCT04858334

NRG-GI008 CIRCULATE-US

Principal Investigator: Mohammad Talal Khan, DO

Title: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital

Status: Accruing

ClinicalTrials.gov Link: NCT05174169

 

Supportive Care Studies

SW Distress Survey

Principal Investigator: Peter Bushunow, MD

Title: Study of Patient Experiences with Psychosocial Distress Screening at the Lipson Cancer Institute

Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital

Status: Accruing

Locations

Lipson Cancer Institute – Rochester General Hospital
1425 Portland Avenue
Rochester, NY 14621

Lipson Cancer Institute – Linden Oaks
20 Hagen Drive
Suite 100
Rochester, NY 14625

Lipson Cancer Institute – Unity Hospital
1561 Long Pond Road
Suite 120
Rochester, NY 14626